Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
 Investors of March 15, 2016 Lead Plaintiff Deadline in a Class Action Lawsuit - EconoTimes)
SAN FRANCISCO, Feb. 08, 2016 -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors in MannKind Corp. (NASDAQ:MNKD) that there is a March 15, 2016 lead plaintiff deadline in the class action related to the disappointing sales of its flagship insulin inhalant, Afrezza.
If you suffered losses because of your purchases of MannKind securities between August 10, 2015 and January 5, 2016, or have information that will help our investigation contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation by calling 510-725-3000, emailing [email protected] or visiting https://www.hbsslaw.com/cases/MNKD. The lawsuit was filed in the U.S. District Court for the Central District of California and investors have until March 15, 2016 to move the court to participate as a lead plaintiff.
MannKind is a biopharmaceutical company whose main product, Afrezza, is a rapid-acting insulin inhaled at mealtimes to help control insulin levels in adults with type 1 and type 2 diabetes. On January 5, 2016, MannKind issued a press release announcing the termination of its license and collaboration agreement with pharmaceutical distributor Sanofi-Aventis. That same day, Bloomberg reported that the agreement was terminated due to low level of prescriptions despite Sanofi's best efforts. On this news, the company's stock fell $0.70 per share, or over 48%, to close at $0.75 per share on January 5, 2015.
Then, on January 6, 2015, an article published in the LA Times stated that Afrezza was unsuccessful because the doctors tasked with carrying out FDA-mandated lung testing on Afrezza patients were unfamiliar with the tests, and didn’t prescribe Afrezza as a result. On this news, the company's stock fell further, by approximately 2.67%, to close at $0.73 per share on January 6, 2015.
The complaint alleges that defendants misled investors by failing to disclose that, in spite of MannKind’s assurances, the FDA’s required testing was impeding sales of Afrezza. As a result, their statements throughout the class period were false and / or misleading and lacked a reasonable basis, in violation of the securities laws.
Whistleblowers: Persons with non-public information regarding MannKind should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
